JLBC
GRCE

J.L. Bainbridge & Co’s Grace Therapeutics GRCE Stock Holding History

J.L. Bainbridge & Co’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,336
Closed -$30K – 83
2020
Q2 		$30K Hold
1,336
– – 0.01% 71
2020
Q1 		$24K Hold
1,336
– – ﹤0.01% 72
2019
Q4 		$157K Buy
1,336
+417
+45% +$41.2K 0.02% 82
2019
Q3 		$83K Buy
+919
New +$85.1K 0.01% 78

Other funds holding GRCE

Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
MMPW
Mitchell McLeod Pugh & Williams Mobile, Alabama $678M AUM 23.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SIAP
Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $599M AUM 28.66% 1-Year Est. Return

J.L. Bainbridge & Co's GRCE Position: Q3 2020 in Review

J.L. Bainbridge & Co sold out of Grace Therapeutics (GRCE) in Q3 2020, closing a stake of 1,336 shares — an estimated $30K sold.

J.L. Bainbridge & Co first reported a position in GRCE in Q3 2019 and held it in 4 quarters. The position peaked at $157K in Q4 2019. 24 funds tracked by Wall St. Rank hold GRCE as of Q3 2020.

  • J.L. Bainbridge & Co reported no remaining Grace Therapeutics position as of Q3 2020 after selling out during the quarter.
  • J.L. Bainbridge & Co sold 1,336 Grace Therapeutics shares in Q3 2020, an estimated $30K.
  • J.L. Bainbridge & Co first reported a position in Grace Therapeutics in Q3 2019 and held it in 4 quarters.
  • J.L. Bainbridge & Co's Grace Therapeutics position peaked at $157K in Q4 2019.
  • 24 funds tracked by Wall St. Rank held Grace Therapeutics as of Q3 2020.

Based on J.L. Bainbridge & Co's 13F filing for Q3 2020, filed 12 Nov 2020.